Transient elastography: a new noninvasive method for assessment of hepatic fibrosis

Sandrin, Laurent; Fourquet, Bertrand; Hasquenoph, Jean-Michel; Yon, Sylvain; Fournier, C.; Mal, F.; Christidis, Christos; Ziol, Marianne; Poulet, Bruno; Kazemi, Farhad; Beaugrand, Michel; Palau, R.

doi:10.1016/j.ultrasmedbio.2003.07.001

Cited by 2,466 publications

(2,072 citation statements)

References 32 publications

Supporting

Mentioning

1,958

Contrasting

Unclassified

Order By: Relevance

“…The principles and examination procedures for such an assessment have been previously published. 17 In addition, the hepatic steatosis levels in 2012 and 2013 were determined by using a controlled attenuation parameter (CAP) designed to measure the liver ultrasonic attenuation at 3.5 MHz by using signals acquired with Fibroscan. Detailed descriptions of the CAP have also been previously published.…”

Section: Methodsmentioning

confidence: 99%

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study

et al. 2015

View full text Add to dashboard Cite

Recently, the beneficial effects of increased physical activity (PA) on nonalcoholic fatty liver disease (NAFLD) in obese subjects were reported. However, the optimal strength and volume of PA in lifestyle modification to improve NAFLD pathophysiology and be recommended as an appropriate management of this condition are unclear. The primary goal of this retrospective study was to estimate the beneficial effects of a varying volume of moderate to vigorous intensity PA (MVPA) on the improvement of NAFLD. A total of 169 obese, middle-aged men were enrolled in a 12-week weight reduction program through lifestyle modification consisting of dietary restrictions plus aerobic exercise. Among these obese subjects, 40 performed MVPA for <150 minÁwk 21 , 42 performed MVPA for 150-250 minÁwk 21 , and 87 performed MVPA for >250 minÁwk 21 . The subjects in the MVPA !250 minÁwk 21 group, in comparison with those in the MVPA <250 minÁwk 21 group, showed significantly attenuated levels of hepatic steatosis (231.8% versus 223.2%). This attenuation was likely independent of the detectable weight reduction. MVPA for !250 minÁwk 21 in comparison with that for <150 minÁwk 21 led to a significant decrease in the abdominal visceral adipose tissue severity (240.6% versus 212.9%), levels of ferritin (213.6% versus 11.5%), and lipid peroxidation (215.1% versus 22.8%), and a significant increase in the adiponectin levels (117.1% versus 15.6%). In association with these changes, the gene expression levels of sterol regulatory element-binding protein-1c and carnitine palmitoyltransferase-1 in peripheral blood mononuclear cells also significantly decreased and increased, respectively. Conclusion: MVPA for !250 minÁwk 21 as part of lifestyle management improves NAFLD pathophysiology in obese men. The benefits seem to be acquired through reducing inflammation and oxidative stress levels and altering fatty acid metabolism. (HEPATOLOGY 2015;61:1205-1215

show abstract

Section: Methodsmentioning

confidence: 99%

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, it measures a novel, i.e., mechanical quality of the liver related to fibrosis and, when compared to biopsy, samples a 100-fold larger volume (4 ϫ 1 cm, Ϸ1/500 of the liver). More than 100 clinical studies correlating ultrasound elastography with liver biopsy have appeared since its first description in 2003, 100 including meta-analyses. [101][102][103] These show a good correlation of stiffness values with the histological stage of fibrosis.…”

Section: Noninvasive Means To Assess Liver Fibrosis and Fibrogenesismentioning

confidence: 99%

Targeting Liver Fibrosis

2009

View full text Add to dashboard Cite

We have made striking progress in our understanding of the biochemistry and cell biology that underlies liver fibrosis and cirrhosis, including the development of strategies and agents to prevent and reverse fibrosis. However, translation of this knowledge into clinical practice has been hampered by (1) the limitation of many in vitro and in vivo models to confirm mechanisms and to test antifibrotic agents, and (2) the lack of sensitive methodologies to quantify the degree of liver fibrosis and the dynamics of fibrosis progression or reversal in patients. Furthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fibrosis and fibrosis progression alone are merely plausible surrogates for future clinical deterioration. In this review we focus on an optimized strategy for preclinical antifibrotic drug development and highlight the current and future techniques that permit noninvasive assessment and quantification of liver fibrosis and fibrogenesis. The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents. (HEPATOLOGY 2009;50:1294-1306

show abstract

“…Of the patients with a Fibroscan Ͻ5.1 kPa, 93% were stage F0 or F1, whereas those with a score Ն7.6 kPa, 94% were stage F2 or higher. 130 A large study of 327 patients with HCV concluded that transient elastography was a reliable tool for the detection of significant fibrosis or cirrhosis. 6 The areas under the ROC were 0.79 for ϾF2, 0.91 for ϾF3, and 0.97 for F4, with liver biopsy used as the reference standard.…”

Section: Novel Imaging Modalities Transient Elastographymentioning

confidence: 99%